NextBio

Help
Description: Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. The combination of the two components acts synergistically and is more effective in vitro than each component alone.
Drug Type: Small Molecule; Approved
Pharmacology: Quinupristin is a streptogramin antibiotic, derived from pristinamycin I.
Mechanism of Action: Quinupristin inhibits the late phase of protein synthesis in the bacterial ribosome.
Indication: For the treatment of bacterial infections (usually in combination with dalfopristin).
Half Life: 3.1 hours
View Complete Description



Associated Researchers

Help for Associated Researchers

Thought leaders and organizations working on research involving Quinupristin.

View All Author iconAuthors
  • Peter C Appelbaum
  • Ian Morrissey
  • S Pereyre
  • I Spiliopoulou
  • David J Farrell
View All Clinical trial sponsors icon Clinical Trials Sponsors
  • National Eye Institute (NEI)
  • Cubist Pharmaceuticals
  • Oregon Health and Science University
  • Bayer
  • National Institute of Allergy and Infectious Diseases (NIAID)
View All Affiliations icon Organizations
  • Hershey Medical Center
  • Université Catholique de Louvain
  • Beth Israel Deaconess Medical Center
  • Université Victor Segalen Bordeaux 2
  • University of Würzburg

Clinical Trials | 9 trials

Help for Clinical Trials View All

Community

Help for Community
NextBio Users

  • No NextBio users were found for “Quinupristin”.
    Complete your user profile with your interests, if you want others to find you within the NextBio community.

NextBio Groups

  • No NextBio groups were found for “Quinupristin”.
    Be the first to start a group and share your interests with others within the NextBio community.

© 2010 NextBio